特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
938688

慢性膵炎 (CP) - 市場考察、疫学、市場予測:2030年

Chronic pancreatitis (CP) - Market Insights, Epidemiology and Market Forecast-2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 159 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.89円
慢性膵炎 (CP) - 市場考察、疫学、市場予測:2030年
出版日: 2020年05月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、慢性膵炎 (CP) 市場について調査分析し、概要、過去・将来の疫学、欧州5ヶ国 (ドイツ、スペイン、イタリア、フランス) と日本の市場動向に焦点を当てて、現在の治療法、新薬、治療別の市場シェア、市場規模の実績・予測などについて、体系的な情報を提供しています。

目次

第1章 主な考察

第2章 慢性膵炎 (CP) の概要

第3章 慢性膵炎 (CP) のSWOT分析

第4章 慢性膵炎 (CP) 市場の概要

  • 2017年のCPの市場シェア分布
  • 2030年のCPの市場シェア分布

第5章 疾患の背景と概要

  • イントロダクション
  • 関連する危険因子と分類システム
  • 病因
  • 病態生理
  • 再発性慢性膵炎 (CP) から慢性膵炎 (CP) への進行のメカニズムとバイオマーカー
  • CPの合併症
  • CPの診断

第6章 疫学と患者集団

  • 主な調査結果
  • 慢性膵炎 (CP) の総患者数

第7章 慢性膵炎 (CP) の国別の疫学

  • 米国
    • 前提条件と根拠
    • 有病率
    • 診断症例数
    • 病因に基づく有病率
    • 有病率:性別
    • 臨床症状
  • 欧州5ヶ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 有病率
    • 診断症例数
    • 病因に基づく有病率
    • 有病率:性別
    • 臨床症状

第8章 慢性膵炎 (CP) の治療と管理

  • CPの臨床管理
  • ACG臨床ガイドライン:慢性膵炎 (CP)
  • 慢性膵炎 (CP) の管理に関するNICEガイドライン
  • 慢性膵炎 (CP) の管理に関する日本のガイドライン
  • HaPanEUのイニシアチブ
  • 慢性膵炎 (CP) の内視鏡治療:ESGEガイドライン
  • 慢性膵炎 (CP) の疼痛
  • ケーススタディ
  • 患者の旅

第9章 アンメットニーズ

第10章 上市薬

  • Viokace:Aptalis Pharma
    • 製品説明
    • 製品開発活動
    • 臨床開発
    • 安全性と有効性
  • Zenpep:Aptalis Pharma
  • Pertzye:Digestive Care, Inc

第11章 新薬

  • NI-03: Kangen Pharma
  • MS-1819:AzurRX BioPharma

第12章 その他の有望な候補薬

  • TLY012:Theraly Fibrosis

第13章 慢性膵炎 (CP) :主要7市場分析

第14章 国別の市場規模

第15章 市場促進要因

第16章 市場の障壁

第17章 付録

章18章 DelveInsightの能力

第19章 免責事項

章20章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Chronic Pancreatitis (CP) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Sensitivity, Specificity, Advantages, and Disadvantages of Diagnostic Tests for Chronic Pancreatitis
  • Table 3: Diagnosed Incident Population of Chronic Pancreatitis in 7MM (2017-2030)
  • Table 4: Prevalence of Chronic Pancreatitis in the United States in the United States (2017-2030)
  • Table 5: Diagnosed cases of Chronic Pancreatitis in the United States (2017-2030)
  • Table 6: Prevalence of Chronic Pancreatitis based on Etiology in the United States (2017-2030)
  • Table 7: Gender-specific Prevalence of Chronic Pancreatitis in the United States (2017-2030)
  • Table 8: Clinical manifestation of Chronic Pancreatitis in the United States (2017-2030)
  • Table 9: Prevalence of Chronic Pancreatitis in Germany in Germany (2017-2030)
  • Table 10: Diagnosed cases of Chronic Pancreatitis in Germany (2017-2030)
  • Table 11: Prevalence of Chronic Pancreatitis based on Etiology in Germany (2017-2030)
  • Table 12: Gender-specific Prevalence of Chronic Pancreatitis in Germany (2017-2030)
  • Table 13: Clinical manifestation of Chronic Pancreatitis in Germany (2017-2030)
  • Table 14: Prevalence of Chronic Pancreatitis in France in France (2017-2030)
  • Table 15: Diagnosed cases of Chronic Pancreatitis in France (2017-2030)
  • Table 16: Prevalence of Chronic Pancreatitis based on Etiology in France (2017-2030)
  • Table 17: Gender-specific Prevalence of Chronic Pancreatitis in France (2017-2030)
  • Table 18: Clinical manifestation of Chronic Pancreatitis in France (2017-2030)
  • Table 19: Prevalence of Chronic Pancreatitis in Italy in Italy (2017-2030)
  • Table 20: Diagnosed cases of Chronic Pancreatitis in Italy (2017-2030)
  • Table 21: Prevalence of Chronic Pancreatitis based on Etiology in Italy (2017-2030)
  • Table 22: Gender-specific Prevalence of Chronic Pancreatitis in Italy (2017-2030)
  • Table 23: Clinical manifestation of Chronic Pancreatitis in Italy (2017-2030)
  • Table 24: Prevalence of Chronic Pancreatitis in Spain in Spain (2017-2030)
  • Table 25: Diagnosed cases of Chronic Pancreatitis in Spain (2017-2030)
  • Table 26: Prevalence of Chronic Pancreatitis based on Etiology in Spain (2017-2030)
  • Table 27: Gender-specific Prevalence of Chronic Pancreatitis in Spain (2017-2030)
  • Table 28: Clinical manifestation of Chronic Pancreatitis in Spain (2017-2030)
  • Table 29: Prevalence of Chronic Pancreatitis in the United Kingdom in the United Kingdom (2017-2030)
  • Table 30: Diagnosed cases of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Table 31: Prevalence of Chronic Pancreatitis based on Etiology in the United Kingdom (2017-2030)
  • Table 32: Gender-specific Prevalence of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Table 33: Clinical manifestation of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Table 34: Diagnosed Incidence of AP by Etiology in the UK (2017-2030)
  • Table 35: Diagnosed Incidence of AP by Severity in the UK (2017-2030)
  • Table 36: Diagnosed Incidence of AP by Gender in the UK (2017-2030)
  • Table 37: Diagnosed Incidence of Recurrent AP Cases in the UK (2017-2030)
  • Table 38: Prevalence of Chronic Pancreatitis in Japan in Japan (2017-2030)
  • Table 39: Diagnosed cases of Chronic Pancreatitis in Japan (2017-2030)
  • Table 40: Prevalence of Chronic Pancreatitis based on Etiology in Japan (2017-2030)
  • Table 41: Gender-specific Prevalence of Chronic Pancreatitis in Japan (2017-2030)
  • Table 42: Clinical manifestation of Chronic Pancreatitis in Japan (2017-2030)
  • Table 43: 7 Major Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 44: 7 Major Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 45: United States Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 46: US Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 47: Germany Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 48: Germany Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 49: France Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 50: France Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 51: Italy Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 52: Italy Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 53: Spain Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 54: Spain Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 55: United Kingdom Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 56: The UK Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Table 57: Japan Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Table 58: Japan Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: TIGAR-O risk factor classification system
  • Figure 3: Effects of ethanol on acinar and pancreatic stellate cells
  • Figure 4: Pathophysiology of chronic pancreatitis
  • Figure 5: Pathophysiology of chronic pancreatitis
  • Figure 6: Prevalent Population of Chronic Pancreatitis in 7MM (2017-2030)
  • Figure 7: Prevalence of Chronic Pancreatitis in the United States in the United States (2017-2030)
  • Figure 8: Diagnosed cases of Chronic Pancreatitis in the United States (2017-2030)
  • Figure 9: Prevalence of Chronic Pancreatitis based on Etiology in the United States (2017-2030)
  • Figure 10: Gender-specific Prevalence of Chronic Pancreatitis in the United States (2017-2030)
  • Figure 11: Clinical manifestation of Chronic Pancreatitis in the United States (2017-2030)
  • Figure 12: Prevalence of Chronic Pancreatitis in Germany in Germany (2017-2030)
  • Figure 13: Diagnosed cases of Chronic Pancreatitis in Germany (2017-2030)
  • Figure 14: Prevalence of Chronic Pancreatitis based on Etiology in Germany (2017-2030)
  • Figure 15: Gender-specific Prevalence of Chronic Pancreatitis in Germany (2017-2030)
  • Figure 16: Clinical manifestation of Chronic Pancreatitis in Germany (2017-2030)
  • Figure 17: Prevalence of Chronic Pancreatitis in France in France (2017-2030)
  • Figure 18: Diagnosed cases of Chronic Pancreatitis in France (2017-2030)
  • Figure 19: Prevalence of Chronic Pancreatitis based on Etiology in France (2017-2030)
  • Figure 20: Gender-specific Prevalence of Chronic Pancreatitis in France (2017-2030)
  • Figure 21: Clinical manifestation of Chronic Pancreatitis in France (2017-2030)
  • Figure 22: Prevalence of Chronic Pancreatitis in Italy in Italy (2017-2030)
  • Figure 23: Diagnosed cases of Chronic Pancreatitis in Italy (2017-2030)
  • Figure 24: Prevalence of Chronic Pancreatitis based on Etiology in Italy (2017-2030)
  • Figure 25: Gender-specific Prevalence of Chronic Pancreatitis in Italy (2017-2030)
  • Figure 26: Clinical manifestation of Chronic Pancreatitis in Italy (2017-2030)
  • Figure 27: Prevalence of Chronic Pancreatitis in Spain in Spain (2017-2030)
  • Figure 28: Diagnosed cases of Chronic Pancreatitis in Spain (2017-2030)
  • Figure 29: Prevalence of Chronic Pancreatitis based on Etiology in Spain (2017-2030)
  • Figure 30: Gender-specific Prevalence of Chronic Pancreatitis in Spain (2017-2030)
  • Figure 31: Clinical manifestation of Chronic Pancreatitis in Spain (2017-2030)
  • Figure 32: Prevalence of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Figure 33: Diagnosed cases of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Figure 34: Prevalence of Chronic Pancreatitis based on Etiology in the United Kingdom (2017-2030)
  • Figure 35: Gender-specific Prevalence of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Figure 36: Clinical manifestation of Chronic Pancreatitis in the United Kingdom (2017-2030)
  • Figure 37: Prevalence of Chronic Pancreatitis in Japan in Japan (2017-2030)
  • Figure 38: Diagnosed cases of Chronic Pancreatitis in Japan (2017-2030)
  • Figure 39: Prevalence of Chronic Pancreatitis based on Etiology in Japan (2017-2030)
  • Figure 40: Gender-specific Prevalence of Chronic Pancreatitis in Japan (2017-2030)
  • Figure 41: Clinical manifestation of Chronic Pancreatitis in Japan (2017-2030)
  • Figure 42: Diagnostic path for chronic pancreatitis
  • Figure 43: Therapeutic path for chronic pancreatitis
  • Figure 44: Patient journey for chronic pancreatitis
  • Figure 45 Unmet needs for Chronic pancreatitis
  • Figure 46: 7 Major Market Size of Chronic Pancreatitis in USD Million (2017-2030)
  • Figure 47: 7 Major Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 48: Market Size of Chronic Pancreatitis in the United States, USD Million (2017-2030)
  • Figure 49: The US Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 50: Market Size of Chronic Pancreatitis in Germany, USD Million (2017-2030)
  • Figure 51: Germany Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 52: Market Size of Chronic Pancreatitis in France, USD Million (2017-2030)
  • Figure 53: France Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 54: Market Size of Chronic Pancreatitis in Italy, USD Million (2017-2030)
  • Figure 55: Italy Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 56: Market Size of Chronic Pancreatitis in Spain, USD Million (2017-2030)
  • Figure 57: Spain Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 58: Market Size of Chronic Pancreatitis in the United Kingdom, USD Million (2017-2030)
  • Figure 59: The UK Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 60: Market Size of Chronic Pancreatitis in Japan, USD Million (2017-2030)
  • Figure 61: Japan Market Size of Chronic Pancreatitis by Therapies in USD Million (2017-2030)
  • Figure 62: Market Drivers
  • Figure 63: Market barriers
目次
Product Code: DIMI0985

DelveInsight's 'Chronic pancreatitis (CP) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CP in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic pancreatitis (CP) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic pancreatitis (CP) - Disease Understanding and Treatment Algorithm

Chronic pancreatitis (CP) is a disease characterized by a syndrome of symptoms and clinical manifestations related to functional abnormalities that develop as the result of glandular fibrosis and atrophy due to acute and chronic inflammation. CP most commonly occurs because of environmental insults, with an increased risk in patients with genetic and/or anatomic predispositions. CP may be preceded by antecedent episodes of Chronic Pancreatitis, but is increasingly recognized in patients without a prior history of AP or abdominal pain.

Current treatments can only provide temporary pain relief and manage complications but are unable to arrest or slow the progression of this often debilitating illness disease-related complications are progressive and generally irreversible. Unfortunately, there are no medical therapies to interrupt or reverse disease progression, so management primarily consists of screening for and providing early management of complications.

The DelveInsight Chronic pancreatitis (CP) market report gives the thorough understanding of the Chronic pancreatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, complications, biomarkers and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Chronic pancreatitisin the US, Europe and Japan.

Chronic pancreatitis Epidemiology

The Chronic pancreatitis (CP) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of Chronic Pancreatitis, Diagnosed cases of Chronic Pancreatitis, Prevalence of Chronic Pancreatitis based on Etiology, Gender-specific Prevalence of Chronic Pancreatitis, Clinical manifestation of Chronic Pancreatitis) scenario of Chronic pancreatitis (CP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Chronic pancreatitis(CP) in 7 MM was found to be 395,137 in the year 2017.

Chronic pancreatitis Drug Chapters

This segment of the Chronic pancreatitis report encloses the detailed analysis of marketed drugs and early stage (Phase-I and Phase-II) pipeline drugs along with other promising candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

A multidisciplinary treatment approach is usually followed internationally for the management of CP and the market consequently can be divided into segments based on revenue generated by therapies which include pain control, management of exocrine and endocrine insufficiency and management of other complications. However, there are important points to be noted such as the fact that there are not curative treatment options at present and all the therapies used are either off-label or symptomatic in nature.

Chronic pancreatitis Market Outlook

The Chronic pancreatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Chronic pancreatitis in 7MM was found to be USD 1865.49 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of CP, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Chronic pancreatitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic pancreatitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic pancreatitis Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Chronic pancreatitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chronic pancreatitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic pancreatitis market
  • To understand the future market competition in the Chronic pancreatitis market.

Table of Contents

1. Key Insights

2. Executive Summary of Chronic Pancreatitis

3. SWOT Analysis for Chronic Pancreatitis

4. Chronic pancreatitis Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of CP in 2017
  • 4.2. Market Share (%) Distribution of CP in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Associated risk factors and classification systems
  • 5.3. Etiology
  • 5.4. Pathophysiology

. Clinical features associated with CP

  • 5.5. Mechanisms and Biomarkers for Progression from Recurrent Chronic Pancreatitis to Chronic Pancreatitis
  • 5.6. Complications of CP
  • 5.7. Diagnosis of CP

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Total Prevalent Population of Chronic Pancreatitis

7. Country Wise-Epidemiology of Chronic Pancreatitis

  • 7.1. The United States
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Prevalence of Chronic Pancreatitis in the United States
    • 7.1.3. Diagnosed cases of Chronic Pancreatitis in the United States
    • 7.1.4. Prevalence of Chronic Pancreatitis based on Etiology in the United States
    • 7.1.5. Gender-specific Prevalence of Chronic Pancreatitis in the United States
    • 7.1.6. Clinical manifestation of Chronic Pancreatitis in the United States
  • 7.2. EU-5
    • 7.2.1. Assumptions and Rationale
    • 7.2.2. Germany
    • 7.2.3. France
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. United Kingdom
  • 7.3. Japan
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Prevalence of Chronic Pancreatitis in Japan
    • 7.3.3. Diagnosed cases of Chronic Pancreatitis in Japan
    • 7.3.4. Prevalence of Chronic Pancreatitis based on Etiology in Japan
    • 7.3.5. Gender-specific Prevalence of Chronic Pancreatitis in Japan
    • 7.3.6. Clinical manifestation of Chronic Pancreatitis in Japan

8. Treatment and Management of Chronic Pancreatitis

  • 8.1. Clinical management of CP
  • 8.2. ACG Clinical Guidelines: Chronic Pancreatitis
  • 8.3. NICE guidelines for the management of Chronic Pancreatitis
  • 8.4. Japanese guidelines for the management of Chronic pancreatitis
  • 8.5. Harmonizing diagnosis and treatment of chronic pancreatitis across Europe (HaPanEU) initiative
  • 8.6. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
  • 8.7. Pain in Chronic Pancreatitis
  • 8.8. Case study
  • 8.9. Patient Journey

9. Unmet needs

10. Marketed Therapies

  • 10.1. Viokace: Aptalis Pharma
    • 10.1.1. Product Description
    • 10.1.2. Product Development Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Safety and efficacy
  • 10.2. Zenpep: Aptalis Pharma
    • 10.2.1. Product Description
    • 10.2.2. Product Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and efficacy
  • 10.3. Pertzye: Digestive Care, Inc
    • 10.3.1. Product Description
    • 10.3.2. Product Development Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and efficacy

11. Emerging Therapies

  • 11.1. NI-03: Kangen Pharma
    • 11.1.1. Product Description
    • 11.1.2. Product Development Activities
    • 11.1.3. Clinical Development
  • 11.2. MS-1819: AzurRX BioPharma
    • 11.2.1. Product Description
    • 11.2.2. Product Development Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and efficacy

12. Other promising candidates

  • 12.1. TLY012: Theraly Fibrosis
    • 12.1.1. Product Description
    • 12.1.2. Product Development Activities

13. Chronic Pancreatitis: 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Total Market Size of Chronic Pancreatitis in 7MM
  • 13.3. Total Market Size of Chronic Pancreatitis by Therapies
  • 13.4. Market Outlook: 7MM

14. Market Size by Country

  • 14.1. United States Market Size
    • 14.1.1. Total Market Size of Chronic Pancreatitis
    • 14.1.2. Market Size of Chronic Pancreatitis by Therapies
  • 14.2. Europe
    • 14.2.1. Germany
    • 14.2.2. France
    • 14.2.3. Italy
    • 14.2.4. Spain
    • 14.2.5. United Kingdom
  • 14.3. Japan: Market Outlook
    • 14.3.1. Total Market Size of Chronic Pancreatitis
    • 14.3.2. Market Size of Chronic Pancreatitis by Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1. Bibliography
  • 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.